FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, namely to oncology, and can be used to treat cancer. A combination of 4,4,4-trifluoro-N - [(1S) -2 - [[(7S) -5- (2-hydroxyethyl) -6-oxo-7H-pyrido [2,3-d] [3] benzazepin-7-yl] amino] -1-methyl-2-oxo-ethyl] butanamide or a pharmaceutically acceptable salt thereof, or hydrate and N- [5- (4-ethyl-piperazin-1-ylmethyl) -pyridin-2-yl] - [5-fluoro-4- (7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazole- 5-yl) -pyrimidin-2-yl] -amine or a pharmaceutically acceptable salt thereof, method and application for the treatment of acute myelogenous leukemia, chronic myelogenous leukemia, breast cancer, ovarian cancer, malignant melanoma, lung cancer, pancreatic cancer, glioblastoma, sarcoma, desmoid tumors, adenocystic carcinoma (ACC), colon and rectal cancer, prostate cancer or medulloblastoma. Also, the invention relates to commercial packaging.
EFFECT: use of inventions makes it possible to inhibit tumor growth due to the synergistic action of the combination.
44 cl, 3 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION THERAPY WITH NOTCH AND PI3K/MTOR INHIBITORS FOR USE IN TREATMENT OF CANCER | 2017 |
|
RU2754452C2 |
| COMBINATION THERAPY FOR TREATMENT OF MAMMARY GLAND CANCER | 2018 |
|
RU2764724C2 |
| QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | 2015 |
|
RU2721723C2 |
| METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTIONS | 2012 |
|
RU2665021C2 |
| METHODS AND COMPOSITIONS TO IMPROVE COGNITIVE FUNCTIONS | 2012 |
|
RU2792010C2 |
| CATHEPSIN-CYSTEINE PROTEASE INHIBITORS | 2003 |
|
RU2312861C2 |
| 5-(7H-PYRROLO[2,3-d]PYRIMIDINE-4-YL)-5-AZASPIRO[2.5]OCTANE-8-CARBOXYLIC ACID DERIVATIVES AS NEW JAK-KINASE INHIBITORS | 2018 |
|
RU2761626C2 |
| TREATMENT OF HYDRADENITIS WITH JAK INHIBITORS | 2020 |
|
RU2805595C1 |
| PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND ITS PHARMACEUTICALLY ACCEPTABLE SALT | 2017 |
|
RU2796400C2 |
| TRICYCLIC COMPOUND AND JAK INHIBITOR | 2015 |
|
RU2674262C2 |
